Posts by Raghu Chivukula, MD, PhD
-
Review: Evidence-Based Management of the Critically Ill Adult with COVID-19
Massachusetts General Hospital physicians have published guidance on treating critically ill adults with COVID-19 that synthesizes the pre-existing critical care literature with emerging data from observational reports and randomized controlled trials.
-
Identification of Novel Bronchiectasis Syndrome Has Implications for Other Respiratory Diseases
Massachusetts General Hospital researchers identified a novel bronchiectasis syndrome caused by mutations that inactivate NEK10, a protein kinase they found to control mucociliary clearance.
-
Cats and Bats and Pangolins: The Origin of Sars-Cov-2
Consensus scientific opinion is that SARS-CoV-2 emerged via a recombination event between related animal coronaviruses.
-
Surfactant Worth Studying as Treatment for COVID-19–Related ARDS
Massachusetts General Hospital researchers believe COVID-19 may represent an unexpected but worthwhile opportunity to revisit the therapeutic potential of administering exogenous surfactant to adults with acute respiratory distress syndrome.
-
Update on Use of Hydroxychloroquine to Treat COVID-19: Q&A with Raghu Chivukula, MD, PhD
Recently, based on clinical data, the FDA and the NIH have each released formal statements expressing concern regarding the safety and efficacy of hydroxychloroquine and chloroquine. In his second Q&A on the subject, Raghu Chivukula, MD, PhD, gives an update on the use of these drugs to treat COVID-19.
-
HCQ Update
Many people are still saying..."[Hydroxychloroquine] is a very strong, powerful medicine...We have some very good results and some very good tests...In France, they had a very good test."
-
Surfactant and COVID-19
To date, trials of surfactant administration in adults have yet to bear fruit, but these negative results may well reflect technical or patient selection issues.
-
Using Chloroquine to Treat COVID-19: Q&A with Raghu Chivukula, MD, PhD
Raghu Chivukula, MD, PhD, a physician-scientist in the Division of Pulmonary and Critical Care Medicine at Massachusetts General Hospital, explains what is currently known about chloroquine and its use to treat COVID-19 patients.
-
The Spectrum of Disordered Inflammation in Critical Illness
Today's FLARE will review what is known about the spectrum of disordered inflammation in critical illness and explore the relationship to COVID-19.
-
Additional Therapeutics for SARS-CoV-2
Today's FLARE focus will be on additional therapeutics for SARS-CoV-2.
Biography
Raghu R. Chivukula, MD, PhD is an Instructor in Medicine at Harvard Medical School, an attending physician in the Massachusetts General Hospital Division of Pulmonary and Critical Care Medicine, and a Visiting Postdoctoral Associate at the Whitehead Institute for Biomedical Research (Sabatini Group). As a physician-scientist, his laboratory interests center on leveraging rare and Mendelian respiratory disorders to inform pulmonary physiology and pathophysiology, with a particular focus on specialized cell organelle biology. His work has been recognized by a Michael A. Shanoff Research Award, selection to Forbes “30 Under 30” in Science and Healthcare, and as a Parker B. Francis Foundation Fellow. Prior to coming to Mass General for residency and fellowship training, he was an undergraduate and MD/PhD student at Johns Hopkins University.
Pulmonary and Critical Care Medicine
The Division of Pulmonary and Critical Care Medicine at Massachusetts General Hospital provides comprehensive care for the full range of respiratory conditions and diseases.